IL7R and acute myeloid leukemia: The results showed that the expression of IL7R showed a negative correlation with the sensitivity of apicidin, belinosta, ciclopirox, cytarabine hydrochloride, and panobinostat, and that IL7R may affect the therapeutic efficacy of AML patients (Fig. 7A).